Sandoz Wins Health Canada Approval for Generic Ozempic

Sandoz Group (SIX:SDZ) announced Friday it has received approval from Health Canada to market its generic version of semaglutide, the active pharmaceutical ingredient in Novo Nordisk's blockbuster diabetes drug Ozempic. The approval marks a key entry for the Swiss generics firm into the highly competitive market for GLP-1 agonists.

Canadian Market Entry

The regulatory authorization permits Sandoz to sell its semaglutide injection for the treatment of adults with type 2 diabetes. The company's entry targets a significant patient population and a lucrative market.

Sandoz highlighted the scale of the opportunity in Canada, citing that:

• Nearly 6 million people in the country have diabetes, the majority with type 2.
• The Canadian market for GLP-1 therapies is estimated to be worth approximately $2.6 billion.

Financial Impact and Context

Ad

Despite the approval, Sandoz clarified that it does not expect a potential launch of the generic semaglutide to make a material profit contribution in the current year. The company also affirmed that the development does not affect its full-year financial guidance for 2026.

The introduction of a generic competitor to Ozempic is a significant development for the Canadian pharmaceutical market. Over time, it could introduce pricing pressure on the brand-name drug and broaden patient access to semaglutide-based treatments.

Global GLP-1 Strategy

This Canadian approval follows a similar authorization Sandoz received for a GLP-1 product in Brazil earlier in 2026. In that market, the company is partnering with Adalvo to commercialize a generic semaglutide product under the brand name Owozy. These moves signal a broader strategic push by Sandoz to capture a share of the global GLP-1 market, which has seen explosive growth.